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SUMMARY 
 Ventricular tachyarrhythmia is one of the main causes responsible for sudden cardiac 
death. The prevention and treatment of these severe tachyarrhythmias is still remained a big 
challenge of cardiology in the industrialized countries. There is increasing evidence that 
statins, which represent the first-line therapy for hyperlipidaemia, may possess lipid-
independent pleiotropic actions, which are associated with an increased release of nitric oxide 
(NO) through the activation of eNOS, and contribute to cardioprotection following chronic 
statin treatment. There is lack of evidence, however, whether statins administered acutely 
influence the severity of arrhythmias, resulting from ischaemia and reperfusion (I/R). 
Therefore, the aim of the present study was to examine the effects and mechanisms of 
acute statin administration on arrhythmias resulting from a 25 min coronary artery occlusion 
and reperfusion (I/R) in chloralose/urethane anaesthetized dogs. In a group of dogs activated 
simvastatin (0.1 mg/kg) was administrated in slow intracoronary injection just prior to the 
occlusion of the left anterior descending coronary artery. The severity of ischaemia (degree of 
inhomogeneity of electrical activation, epicardial ST-segment) and of arrhythmias, as well as 
the plasma NOx levels in blood samples taken from the coronary sinus were assessed. From 
the myocardial tissue samples the activity of eNOS (Western blot) and superoxide production 
(confocal microscopy) were determined. 
 We have shown that compared to the control group, in which the dogs were treated 
only with the solvent of simvastatin, the administration of simvastatin significantly decreased 
the severity of ischaemia and of ventricular arrhythmias, increased the activity of eNOS and 
the plasma concentration of NO metabolites, and significantly reduced the production of 
superoxide during reperfusion. We have also pointed out that the protective effects of 
simvastatin are mediated through the rapid activation of eNOS, most probably via the 
stimulation of PI-3 kinase/Akt pathway, since the inhibition of NOS by L-NAME, and the 
inhibition PI-3 kinase by wortmannin abolished the protective effects of simvastatin. 
 Thus we conclude that the antiarrhythmic effect of acute simvastatin administration 
can certainly be associated with an increased NO bioavailability during occlusion, due to the 
rapid activation of eNOS via the stimulation of the PI3/Akt pathway by simvastatin. 
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1. INTRODUCTION 
1.1. Sudden cardiac death and preconditioning 
The ways of prevention sudden cardiac death (SCD) due to fatal ventricular 
tachyarrhythmias resulting from acute myocardial ischemia have been in the focus of research 
for a long time. One of the earliest papers on this issue came from Harris [1] in 1950, who 
showed that ventricular fibrillation resulting from coronary artery occlusion is less likely to 
occur in dogs if a coronary artery is occluded in two stages; i.e. the complete occlusion is 
preceded by a partial occlusion of the same coronary artery. Somewhat later, Gülker and his 
colleagues [2] examined the effect of multiple coronary artery occlusion on the ventricular 
fibrillation threshold (VFT), and found that the decrease in VFT became increasingly less with 
repeated coronary occlusions. Similarly, in 1983 Barber [3], using serial short (5 min) periods 
of occlusion of the anterior descending coronary artery, showed that the number of ventricular 
ectopic beats during the second occlusion was significantly less than during the first, similar 
period of occlusion, if the reperfusion interval between the occlusions was 3 min. This effect, 
however, abolished if the reperfusion interval between the occlusions was increased to 40 min 
[3]. 
The seminal paper of Murry and his colleagues in 1986 [4] was the first publication, 
which provided evidence that the heart is able to adapt to ischaemic stress; i.e. short periods of 
ischaemia increase the tolerance of the heart to a subsequent more severe and prolonged 
period of ischaemia. This phenomenon was termed as ‘ischaemic preconditioning’ [4]. They 
showed that the metabolic changes and the size of infarct, resulting from a 40 min occlusion of 
the left circumflex coronary artery, is considerably reduced, if this prolonged occlusion was 
preceded by four 5 min periods of occlusion 20 min earlier [4]. Soon after this first description 
of the preconditioning phenomenon, in 1987 Shiki and Hearse [5] reported that repeated, 
similar periods (5 min) of occlusions markedly reduce the reperfusion-induced ventricular 
arrhythmias, if the reperfusion interval between the occlusions did not exceed 20 min. 
Extending the time interval between the occlusions to hours or to days the protection against 
arrhythmias was ceased [5]. If ischaemic preconditioning is considered as it originally defined 
by Murry and his colleagues [4], then the first evidence for the antiarrhythmic effect of 
ischaemic preconditioning was provided by Komori and his colleagues in 1990 [6], and 
somewhat later in 1992, using a large animal model, Végh and her colleagues [7]. These 
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studies clearly showed in two species (rats and dogs) that preconditioning provides marked 
protection against the ischaemia and reperfusion-induced serious, often fatal ventricular 
arrhythmias [6, 7]. 
There appears to be no doubt that ischaemic preconditioning is a general phenomenon; 
the protection can be induced in all species thus far investigated, including humans, suggesting 
possible clinical exploitation of the phenomenon. However, these expectations have been 
disappointed by two observations; i.e. (1) that the protection resulting from preconditioning is 
short-lived (it lasts only for one or two hours, then it disappears), and (2) that coronary artery 
occlusion, apart from some acute surgical and/or interventional cardiologic manoeuvres, 
cannot be applied as a preconditioning stimulus in human. These disappointments were, 
however, largely solved by two observations, giving further stimulus to continue 
‘preconditioning’ research. For example, it has turned out that there is a second phase of the 
cardioprotection, which occurs 20-24 hours after the initial preconditioning stimulus. This 
“delayed” or “second window of protection” has raised a considerable interest and facilitated 
further investigations for the exploration of this phenomenon [8-10]. Furthermore, in 1991 
Végh and her colleagues [11] provided the first evidence that not only the brief ischaemic 
episodes, but rapid pacing of the heart through the right ventricle, may evoke protection 
against the ischaemia and reperfusion-induced arrhythmias. Also, they showed that heavy 
physical exercise is an effective stimulus to induce a preconditioning-like cardioprotection 
[12]. Since then it becomes obvious that protection, similar to that results from ischaemic 
preconditioning, can be induced by several stimuli, like partial coronary artery occlusion, 
hypoxia, increased myocardial stretch, or by various drugs that may use similar pathways to 
elicit protection than preconditioning itself. 
The mechanisms involved in the preconditioning-induced adaptive phenomenon have 
also raised considerable interest both in experimental and clinical point of view. A number of 
hypotheses have been raised to explain the mechanisms involved in cardioprotection 
associated with preconditioning. Among these, perhaps the most accepted one is, which 
emphasizes the involvement of endogen substances in the induction and mediation of the 
protection [13]. According to this, endogenous substances (both protective and injurious) are 
generated and released from the myocardium in response to the transient ischaemic stress, 
resulting from the preconditioning stimulus. These substances are then activating their 
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receptors, stimulate various signalling pathways and modify myocardial function, leading to 
cardioprotection. 
The first endogen substances that related to the preconditioning-induced protection 
were prostacyclin [14] and adenosine [15, 16]. For example, in 1990 Végh and her colleagues 
[14] demonstrated in anaesthetized dogs that the inhibition of the cyclooxygenase pathway by 
meclofenamate markedly attenuates the antiarrhythmic effect of preconditioning. Almost at 
the same time the Downey’s group provided evidence that adenosine, plays a crucial role in 
the preconditioning-induced cardioprotective effect [15]. They proposed that adenosine by 
activating the Gi-protein coupled adenosine A1 receptor leads to the translocation of protein 
kinase C (PKC) from the cytosol to the membrane, resulting in the opening of sarcolemmal 
ATP-sensitive potassium channels [16, 17]. The role of ATP channels in the preconditioning-
induced cardioprotection is supported that the protection was abolished by the ATP-sensitive 
potassium channel blocker glibenclamide [17]. 
There is some evidence that reactive oxygen species (ROS) may also play a trigger role 
in the preconditioning-induced protection [18, 19]. The short periods of preconditioning 
ischaemia and reperfusion insult, result in early ROS generation via the opening of the 
mitochondrial ATP-sensitive potassium channels (mitoKATP), and the influx of potassium ion 
influx into the mitochondria [20]. 
Besides the ‘adenosine hypothesis’ proposed by the Downey’s group [15], our research 
group, in the Department of Pharmacology and Pharmacotherapy at the University of Szeged, 
suggested an alternative hypothesis for mechanisms involved in the preconditioning-induced 
protection against arrhythmias. It was hypothesized that, more than likely, several mediators 
are generated and released in response to the preconditioning stimuli, not only from the 
cardiac myocytes, but also form the vascular endothelium. These endothelium-derived 
substances would modify arrhythmogenesis by direct communication with cardiac myocytes. 
It was shown that bradykinin, which is rapidly formed in the blood during hypoxia [21-23] 
plays an important trigger role in the preconditioning-induced protection, since it acting on the 
endothelial bradykinin B2 receptors triggers the generation and release of other mediators, 
such as prostacyclin[14] and nitric oxide [24]. These diffusible mediators reaching the 
myocytes activate mechanisms, which are ultimately lead to the protection [25]. The 
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involvement of bradykinin in the cardioprotective effect of preconditioning was confirmed by 
others as well [26, 27]. 
Our research group was the first to propose that nitric oxide (NO) plays a mandatory 
role in the cardioprotective effect of preconditioning. The most likely scenario is that NO by 
stimulating soluble guanylyl cyclase elevates cGMP, which could modify arrhythmogenesis, 
for example, by suppressing calcium entry into the cell through L-type calcium channels [28]. 
There is abundant evidence that NO plays a major role, both as a trigger and a mediator, in the 
preconditioning-induced early and delayed protection [10, 29-31]. 
Under physiologic conditions NO is synthesized by NOS enzymes, among which the 
endothelial isoform (eNOS) has the major role in NO formation to regulate vascular tone, 
inhibit platelet aggregation, or to achieve negative inotropic effect on the myocardium [32, 
33]. The other two isoforms, such as the neuronal (nNOS) and the inducible (iNOS) enzymes 
may also have a role in NO production both under physiological and pathophysiological 
conditions. These isoforms differ in their localisation, dependence on Ca2+, as well as in their 
expression and activities. Both eNOS and nNOS are Ca2+-dependent enzymes, they are 
activated, when the level of intracellular Ca2+ becomes elevated [34]. In contrast, the 
activation of iNOS does not require calcium; it is activated by other factors, such as cytokines 
or tumour necrosis factor and largely involved in myocardial depression associated with sepsis 
[35]. Interestingly, it has been proved that the activation of iNOS, by producing NO, is the part 
of that pathway, which is involved in the delayed phase of the cardioprotection afforded by 
preconditioning [31, 34, 36, 37]. 
Most of the effects of NO, such as vasodilatation, inhibition of platelet aggregation, 
reduced myocardial contractility, are mediated through the activation of guanylyl cyclase and 
the resulting elevation of cGMP [28, 38]. Furthermore, NO regulates calcium homeostasis 
within the cell by enhancing calcium uptake into the sarcoplasmic reticulum [39], directly 
inhibits Ca2+ influx across L-type calcium channels of the cardiomyocytes [40], modifies 
noradrenaline release from nerve endings [41], regulates free radical formation and protects 
the myocardium against reperfusion injury [42, 43]. Some of these effects are not mediated by 
cGMP; there is increasing evidence that NO may modify processes and functions by a cGMP-
independent way, with S- nitrosylation [44]. Nevertheless, all these above mentioned effects 
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and mechanisms of NO may somehow contribute to the antiarrhythmic effect of 
preconditioning. 
Another important step in the research of preconditioning was the recognition that 
certain drugs may induce protection similar to that of preconditioning. The idea of the “drug-
induced preconditioning „came from the assumption that if endogenous substances are, 
indeed, involved in the preconditioning-induced protection, and that their synthesis and the 
release become impaired under pathophysiological conditions, then drugs, which are able to 
replace or modify the production of these mediators, would elicit protection. One of the first 
attempts to pharmacological preconditioning was the use of adenosine and its analogues like 
acadesine [45]. However, the clinical exploitation of these drugs is largely limited by the 
strong hypotensive and bradycardiac effects, and that tachyphylaxis may develop after their 
administration. There was, however, more success with the use of organic nitrites and nitrates 
as well as the angiotensin converting enzyme (ACE) inhibitors. These drugs have been using 
for a long time in the treatment of angina pectoris, hypertension and heart failure. The 
recognition that nitrites and nitrates act by donating NO (NO donors) and that ACE 
participates in the degradation of bradykinin, make these drugs candidate for pharmacological 
preconditioning. Indeed, we have substantial evidence that the KATP channel opener and NO 
donor nicorandil [46] and the ACE-NEP inhibitor Z13752A [47] by reducing the degradation 
of bradykinin, mimic the antiarrhythmic effects of preconditioning. More recently we showed 
that the inorganic sodium nitroprusside [48] and sodium nitrite [49] by donating NO provides 
marked protection against arrhythmias, resulting from ischaemia and reperfusion. 
Beyond the abovementioned drugs, clinical studies suggest that statins may provide 
protection against the severe ventricular arrhythmias and sudden cardiac death [50-52]. These 
drugs were originally developed for the treatment of hypercholesterolemia, but it turned out 
that some of the cardiovascular protective effects are independent from their lipid lowering 
effect. 
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1.2. Statins in the treatment of cardiovascular diseases 
In the 1950s it became obvious that the 
elevated level of cholesterol in plasma mainly 
contributes to the cardiovascular diseases [53]. 
Since in those times there was no clear clinical 
evidence for the benefit of cholesterol level 
reduction, the interest for developing cholesterol 
lowering drugs was marginalized. In the following 
years numerous studies confirmed the therapeutic 
advantage of the decrease of cholesterol synthesis, 
pointing out that a reduction in the elevated 
plasma levels of LDL with diet and drugs 
decreases the risk of cardiovascular diseases [54]. 
One of the possibilities by which cholesterol 
formation can be reduced is the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase, which is a rate limiting enzyme of cholesterol synthesis (Figure 1). The first 
HMG-CoA reductase inhibitor was ML236B (Compacting), which had been found in a 
fermentation broth of Penicillium citrinum during the search for an antimicrobial agent [55]. 
This substance has been shown to reduce cholesterol level by 30% in rats [55]. Somewhat 
later, in a fermentation broth of Aspergillus terreus, an even more potent inhibitor of HMG-
CoA reductase was found, that we now know as lovastatin [56]. Since then, the research for 
novel drugs with lipid lowering effect has been accelerated; as a result, several drugs, termed 
as statins (simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin), were developed 
[57]. 
 Recently statins are widely used to lower cholesterol level. Their primary effect is the 
competitive inhibition of HMG-CoA reductase, which is the rate-limiting enzyme of the 
mevalonate pathway, producing cholesterol and isoprenoid (Figure 1). Mitigation of 
cholesterol synthesis leads to enhanced synthesis of LDL receptors, resulting in increased 
absorption of low-density lipoprotein from the plasma, and decreased cholesterol level. Since 
they have also a salutary effect on the lipid composition of plasma, due to an increase in high 
density lipoprotein (HDL) cholesterol and a decrease in triglyceride levels, statins play an 
Figure 1. Statins: the HMG-
CoA reductase inhibitors 
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important role in the treatment of patients with hyperlipidemia, and subsequently, with 
cardiovascular diseases. 
 Statins can be classified on the basis of their effectiveness to reduce lipid levels 
(rosuvastatin = atorvastatin > simvastatin > lovastatin > pravastatin). The differences are 
derived from the strength of binding between statins and HMG-CoA reductase [58]. Statins 
may also classify according to their lipid solubility; e.g. simvastatin, atorvastatin, lovastatin 
and fluvastatin are lipophilic, while rosuvastatin and pravastatin hydrophilic, and to their 
chemical structure; i.e. whether the certain drug is a lactone pro-drug, which is converted to 
active beta-hydroxyl form in the gut, like simvastatin and lovastatin, or exists in active form 
having an open lactone ring, like atorvastatin, fluvastatin, pravastatin and rosuvastatin [59]. In 
respect of manufacturing, we distinguish synthetic products (atorvastatin, cerivastatin, 
fluvastatin and rosuvastatin) and molecules that are produced by fermentation (e.g. pravastatin 
from Nocardia autotrophica, simvastatin from Aspergillus terreus) [57-61]. 
1.3. Pleiotropic effects of statins 
There is increasing experimental and clinical evidence that statins, beyond their lipid 
lowering effects, are able to reduce the incidence of fatal ventricular arrhythmias, which are 
the major cause of mortality in various cardiovascular diseases [50-52, 62, 63]. Since 
cardioprotection by statins was also observed under normocholesterolemic conditions [64-67], 
it was proposed that these drugs might have cholesterol-independent, pleiotropic effects as 
well [68, 69]. These include plaque stabilization and improvement in vascular endothelial 
function [70], reduction in oxidative stress-induced injury [71-73], inhibition of inflammatory 
[74, 75] and thrombogenic responses [69]. Most of these effects are thought to play a role in 
the anti-arrhythmic action of statins [66, 76, 77], and would explain the observed reduction in 
cardiac death in patients with statin treatment [78, 79]. The salutary effects, unrelated to the 
cholesterol lowering action of statins, are proposed to involve both nitric oxide (NO)-
dependent and NO-independent mechanisms [65, 80]. For example, statins have been found to 
increase the generation of NO via eNOS activation [81-83], enhance the formation of 
prostanoids [84] and induce heme-oxygenase-1 [85]. 
Perhaps, the most likely mechanism by which statins provide protection against 
ischaemia and reperfusion-induced arrhythmias is their ability to increase NO synthesis [65, 
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82, 86]. There is substantial previous evidence that NO plays an essential role in both the early 
and delayed anti-arrhythmic effects of preconditioning, induced either by brief periods of 
coronary artery occlusion [29], cardiac pacing [30, 31] or heavy physical exercise [12]. It was 
also demonstrated that these preconditioning stimuli, via the activation of eNOS, enhance NO 
production and modify myocardial function during ischaemia and reperfusion [87]. More 
recently it was showed that pacing induces an immediate increase in eNOS activation and NO 
production, but it also causes an up-regulation of eNOS gene and protein expressions 12 and 
24h later [88]. 
Although the precise mechanism through which statins yield cardioprotection is still 
not well established, clinical and experimental studies suggest that NO, generated via the 
activation of eNOS, may play a mandatory role [89-91]. The mechanisms by which statins 
may activate eNOS are even less understood; the prevention of the oxLDL-mediated down-
regulation of eNOS mRNA and protein levels [92], as well as the up-regulation of eNOS by 
blocking the synthesis of those isoprenoid intermediates of the cholesterol synthesis pathway 
that are involved in the posttranslational modiﬁcation of proteins which regulate eNOS 
expression [81, 93], were suggested as potential mechanisms for eNOS activation during 
chronic statin administration. There are, however, only a few studies which have attempted to 
examine the acute effects of statins; these were related to the assessment of infarct size [94-96] 
and post-ischaemic contractile dysfunction [97]. One of the possible pathways that has been 
proposed to activate eNOS through phosphorylation within minutes, would be the PI 3-
kinase/Akt signalisation [95, 98]. Indeed, Kureishi and his colleagues [98] have demonstrated 
that following acute simvastatin administration, the activation of the PI 3-kinase/Akt/eNOS 
cascade is involved in the increase of NO synthesis in endothelial cells. Similarly, Wolfrum 
and his colleagues [95] showed that in anaesthetised rats subjected to coronary artery 
occlusion, the administration of simvastatin just prior to reperfusion, markedly reduced infarct 
size, increased PI 3-kinase activity, as well as Akt Ser473 and eNOS Ser1177 phosphorylation 
[95]. There is, however, no study which has examined how a single dose of simvastatin 
influences the acute ischaemia and reperfusion induced severe ventricular arrhythmias. To 
answer this question, two studies were designed and performed. 
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2. AIMS OF THE STUDY 
The purpose of the present thesis was to answer the question whether a single dose of 
simvastatin would modify the acute ischaemia and reperfusion induced severe, often life-
threatening ventricular arrhythmias. If so, what might be the mechanism? We have designed 
two separate studies in order to obtain answers for these questions, and the results were 
published in the enclosed publications. Our questions were as follows: 
a) Despite the number of clinical evidence that chronic statin treatment in patients reduces the 
mortality due to sudden cardiac death, there is no sufficient information as to whether the 
acute simvastatin administration would elicit a similar salutary effect. Therefore, we 
designed studies in which we have examined in our established canine model, whether a 
single bolus injection of simvastatin prior to an ischaemia and reperfusion insult would 
modify the severity of ventricular arrhythmias. We have also examined whether nitric oxide 
(NO) is involved in the acute effect of simvastatin. 
b) Since we have found that the acute administration of simvastatin provides marked 
protection against the ischaemia and reperfusion-induced severe ventricular arrhythmias 
and that this antiarrhythmic effect involves the generation of NO by simvastatin, in a 
separate study we have now examined whether this NO formation is mediated through the 
rapid activation eNOS via the stimulation of the PI 3-kinase/Akt signalisation. For this 
purpose we used the PI-3-kinase inhibitor wortmannin prior to the administration of 
simvastatin. 
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3. MATERIALS AND METHODS 
3.1. Experimental animals and ethical concerns 
Adult mongrel dogs of both sexes with a mean body weight of 23 ± 1 kg were used. The 
origin and upkeep of these dogs were in accord with Hungarian law (XXVIII, chapter IV, 
paragraph 31) regarding large experimental animals which conforms with the Guide for the 
Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996). 
3.2. Surgical preparation 
The animals were anaesthetized with pentobarbital (30 mg kg-1 intravenous sodium 
pentobarbitone, Sigma, St. Louis, MO, USA). The right femoral artery was prepared and 
catheterized, through which the dogs were further anaesthetized with a mixture of chloralose 
and urethane (60 and 200 mg kg-1, respectively; Sigma, St. Louis, MO, USA) to maintain 
anaesthesia. The animals were then intubated and ventilated with room air using a Harvard 
respirator (Harvard Apparatus, Natick, MA, USA) at a rate and volume sufficient to maintain 
arterial blood gases and pH within physiological limits [7]. Body temperature was measured 
from the mid-oesophagus and maintained by a heating pad at 37 ± 0.5oC. 
Polyethylene catheters were inserted into the right femoral artery for monitoring arterial 
blood pressure (systolic and diastolic), and via the left carotid artery into the left ventricle (LV) 
for the measurement of systolic (LVSP) and end-diastolic (LVEDP) pressures. From the LV 
pressure curves changes in positive and negative dP/dtmax were calculated. 
The chest was opened at the fifth intercostal space and the anterior descending branch of 
the left coronary artery (LAD) was prepared for occlusion just proximal to the first main 
diagonal branch. Distal to the occlusion site a smaller side branch of the same artery was also 
prepared and cannulated for the local administration of drugs (simvastatin, L-NAME, 
wortmannin and DMSO) and vehicle. Another catheter was positioned through the right 
jugular vein into the coronary sinus to obtain blood samples for the assessment of plasma 
nitrate/nitrite (NOx) levels. In some dogs from each group, the left circumflex (LCX) coronary 
artery was also prepared to measure coronary blood flow (CBF; ml/min-1) by means of a 
transit time Doppler flow probe (Hugo Sachs Electronics, Germany). 
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The severity of myocardial ischaemia was evaluated by changes in the epicardial ST-
segment and in the degree of inhomogeneity of electrical activation. These were measured by 
a composite electrode (containing also four unipolar electrodes by which changes in ST-
segment [mV] were detected) positioned within the potentially ischaemic area as described 
previously [7]. The greatest delay in activation within the ischaemic area following coronary 
artery occlusion was expressed in ms. All parameters, together with a chest lead 
electrocardiogram, were measured with a Plugsys Haemodynamic Apparatus (Hugo Sachs 
Electronics, Germany) and recorded on a Graphtec Thermal Array Recorder (Hugo Sachs 
Electronics, Germany). 
Ventricular arrhythmias were assessed according to the Lambeth conventions [99] with 
that modification as outlined previously [7]. In brief, the total number of ventricular premature 
beats (VPBs), the incidence and the number of episodes of ventricular tachycardia (VT; 
defined as a run of four or more consecutive VPBs at a rate faster than the resting heart rate), 
and the incidence of ventricular fibrillation (VF) were assessed during the occlusion period. 
During reperfusion, only the incidence of VF, which is a fatal event in this species, was 
determined. Dogs that were alive 1-2 min after reperfusion were considered to be survivors. 
The risk area following coronary artery occlusion was assessed by injecting Patent Blue 
V dye into the re-occluded artery using the same method that has been described in detail 
elsewhere [7]. 
3.3. Measurement of plasma nitrate/nitrite (NOx) levels 
These were performed as described previously [100]. Plasma nitrate/nitrite (NOx) 
concentrations were determined by means of the Griess reaction in blood samples taken from 
the coronary sinus at various time intervals as illustrated in Figure 2. After preparation of 
blood samples, the absorbance of the azo compound was measured spectrophotometrically at a 
wavelength of 540 nm and the total nitrate/nitrite (NOx) concentration (µmol l
-1) was 
determined using a standard calibration curve of NaNO2 and NaNO3 (Sigma, St Louis, MO, 
USA). 
3.4. Determination of eNOS phosphorylation by Western blot 
Freshly excised tissue samples from the ischaemic and non-ischaemic regions of the left 
ventricular myocardial wall were immediately frozen in liquid nitrogen and stored at −80°C. 
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100 μg of protein extracts were resolved using 8% sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis and blotted on polyvinylidene fluoride membranes. The blots were 
immunolabeled overnight with a monoclonal mouse anti-eNOS primary antibody (pS1177, 
BD Biosciences) diluted to 1:2500, followed by 1 h incubation with an HRP-conjugated anti-
mouse rabbit secondary antibody (Dako, Danmark) in a dilution of 1:8000. Band densities 
were detected with the ECL Plus kit (GE Healthcare, Buckinghamshire, UK) and developed 
on Amersham HyperfilmTM (GE Healthcare, Buckinghamshire, UK). Pixel intensities of each 
band were measured using ImageJ software (NIH). Three parallel Western blots were 
performed for the statistical analysis using Bonferroni correction. On the blots each examined 
group was compared to the sham-controls. For verifying equal loading, PVDF membranes 
were labelled with Coomassie-Blue. 
An integrated optical density value (the sum of each pixel value corrected to the 
background) was formed by drawing equal size boxes around the bands. The intensities 
obtained from both the total and peNOS bands were normalised to this integrated value. 
3.5. Determination of the functional activity of eNOS by radio immunoassay  
This was performed using a NOS activity assay kit (Cayman Chemical, Ann Arbor, MI, 
USA) based on the biochemical conversion of [3H] L-arginine to [3H] L-citrulline by NOS. 
From the tissue samples (100 mg) membrane proteins were isolated, homogenized in ice-cold 
homogenization buffer (Cayman Chemical, Ann Arbor, MI, USA), and centrifuged at 2000 g 
for 15 min. The supernatant was then ultra-centrifuged at 50000 g for 45 min and the pellet 
(membrane fraction) was re-suspended in the homogenization buffer. A liquid scintillation 
counter was used to determine eNOS activity by measuring the amount of the radio-labelled 
citrulline formed during the reaction, and expressed as the percentage of the total counts 
corrected with the background counts per minute. 
3.6. Assessment of superoxide production 
This was determined by dihydroethidium (DHE; Sigma-Aldrich) fluorescence staining. 
Tissue blocks, excised from the ischaemic myocardial wall were embedded in optimal cutting 
temperature compounds. Cryosections (20 µm) were produced, stained with DHE (1µmol l-1, 
dissolved in pH 7.4 phosphate buffer solution), and incubated at 37oC for 30 min in a dark 
humidified chamber. A negative control was obtained by blocking the reaction with N-acetyl-
L-cysteine (NAC, 100 mmoll-1, Sigma-Aldrich). Both from the stained and the negative 
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control samples 10 to 15 serial images were captured by a confocal laser scanning microscope 
(Olympus FV1000). The intensity of the fluorescent signals were analysed by ImageJ software 
(NIH) and expressed in arbitrary units. 
3.7. Preparation of simvastatin solution  
Before the application of simvastatin (Sigma, St Louis, MO, USA) it has to be converted 
into an active form. A stock solution containing 25 mg simvastatin, dissolved in 625 µl ethanol 
and 937.5 µl 0.1 N NaOH, was prepared and incubated at 50oC for 2 hours. Then the pH of the 
solution was adjusted to 7.0 with 1N HCl and stored at -20°C until use. Immediately prior to 
the experiments an aliquot was taken and diluted in distilled water to obtain the appropriate 
dose. 
3.8. Experimental protocols 
3.8.1. Experimental protocol for the assessment of acute simvastatin administration on the 
ischaemia and reperfusion-induced arrhythmias 
Dogs were randomly selected to form four experimental groups (Figure 2). Control 
dogs (n = 16) were administered the solvent of simvastatin (0.5 ml min-1) in intracoronary 
injection (over 5 min) and subjected to a 25 min occlusion and then reperfusion of the 
descending branch of the left coronary artery (LAD). Fifteen dogs were received activated 
simvastatin in a dose of 0.1 mg kg-1 by the same route, 5 min prior to the onset of the 
occlusion. In another two groups, L-NAME (Sigma) was given in a dose of 5 mg kg-1 also in 
slow intracoronary injection, 15 min before the solvent (L-NAME; n = 12) and the simvastatin 
(n = 11) administration. Eight dogs were used as sham-operated controls (SC; not included in 
the protocol figure).These dogs were only instrumented, without subjecting them to any 
treatment, and from which, after the euthanasia, tissue samples were harvested for measuring 
eNOS phosphorylation and superoxide production. At the end of the experiments the hearts 
were stopped by an excess of the anaesthetic, and myocardial tissue samples were collected 
from both the ischaemic and the non-ischaemic regions of the left ventricular wall for further 
analyses. In at least 5 dogs of each group sample taking was performed at the end of the 25 
min occlusion period, whereas in dogs that had been subjected to reperfusion, tissue samples 
were collected either 5 min after reperfusion (these animals were considered as survivors) or at 
the time when the fibrillation was observed. 
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Figure 2. Experimental protocol for the evaluation of the antiarrhythmic effect of acute 
simvastatin administration. Blood samples (BS) were taken at various time intervals (indicated 
by arrows) from the coronary sinus, and tissue samples (TS) were collected at the end of the 
ischaemic period or 5 min after reperfusion for further biochemical analyses. 
3.8.2. Experimental protocol for the assessment the role of PI 3-kinase/Akt pathway in 
protection provided by the acute simvastatin administration 
In the second series of the experiment, the dogs were randomly selected into five 
experimental groups (Figure 3).The control (C; n=14) and the simvastatin (S; n=12) groups 
were similar to the groups mentioned above. In two other groups, wortmannin alone (W; n=12, 
Sigma) or together with simvastatin (W+S; n=11) was given in a dose of 1.5 mgkg-1 in slow 
intracoronary injection, 15 min before the administration of the solvent and simvastatin. 
Additional 13 dogs were received 0.1% dimethylsulphoxide (DMSO), the solvent of 
wortmannin. Data obtained from 8 dogs in the control and from 6 dogs in the simvastatin 
groups were already used in the first series of experiments. 
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Figure 3. Experimental protocol for the exploration of the IP-3/Akt pathway in the 
antiarrhythmic effect of simvastatin (TS = tissue sample, BS = blood sample). 
3.9. Statistical analysis 
All data are expressed as means ± S.E.M. and the differences between means were 
compared by ANOVA for repeated measures and by the one-way ANOVA as appropriate, 
using the Fisher post hoc test. VPBs and episodes of VT were compared using the Kruskal–
Wallis test. The incidences of arrhythmias (such as VT and VF) and survival from the 
combined ischaemia and reperfusion insult were compared by the Fisher’s exact test. 
Differences between groups were considered significant at P < 0.05. 
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4. RESULTS 
4.1. Evaluation of the effect of acute simvastatin administration on ischaemia and 
reperfusion-induced arrhythmias 
4.1.1. Haemodynamic changes following the administration of solvent, simvastatin and L-
NAME, as well as after coronary artery occlusion 
These are summarized in Table 1 and Table 2. Local intracoronary injection of 
simvastatin and the solvent of simvastatin did not substantially modify the haemodynamic 
parameters and blood flow, measured on the LCX coronary artery. In contrast, the 
administration of L-NAME significantly elevated arterial blood pressure and reduced heart 
rate without substantially modifying the other haemodynamic parameters (Table 1). These 
haemodynamic changes in the L-NAME treated dogs were still present before the onset of the 
LAD occlusion.  
Occlusion of the LAD resulted in significant reductions in arterial blood pressure, LVSP, 
positive and negative dP/dtmax and an increase in LVEDP, whereas the HR remained 
substantially unchanged. These alterations were almost similar in all the examined groups. The 
compensatory blood flow changes, occurring on the LCX when the LAD was occluded, were 
not significantly modified by the administration of simvastatin and L-NAME (Table 2).
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Table 1. Haemodynamic changes following the administration of solvent, simvastatin and L-NAME 
    Solvent       Simvastatin       L-NAME   
  Baseline Change   Baseline   Change   Baseline   Change 
SABP (mmHg) 140 ± 10 3 ± 3 
 
148 ± 8 
 
-4 ± 2 
 
149 ± 7 
 
19 ± 5 * 
DABP (mmHg) 105 ± 6 0 ± 5 
 
101 ± 5 
 
-2 ± 2 
 
104 ± 5 
 
29 ± 5 * 
MABP (mmHg) 117 ± 6 1 ± 4 
 
117 ± 6 
 
-3 ± 2 
 
119 ± 5 
 
25 ± 4 * 
LVSP (mmHg) 154 ± 8 3 ± 3  
158 ± 8 
 
0 ± 2 
 
164 ± 7 
 
13 ± 4 * 
LVEDP (mmHg) 4.6 ± 0.7 0.2 ± 0.3 
 
5.6 ± 0.4 
 
0 ± 0.3 
 
5.1 ± 0.7 
 
0.4 ± 0.3 
+dP/dt (mmHg·s
-1
) 2316 ± 225 99 ± 61  
2795 ± 219 
 
-67 ± 118 
 
2444 ± 242 
 
-124 ± 189 
-dP/dt (mmHg·s
-1
) 2092 ± 260 91 ± 103  
2415 ± 183 
 
-107 ± 81 
 
2172 ± 122 
 
-43 ± 43 
HR (beats·min
-1
) 166 ± 9 5 ± 2  
173 ± 5 
 
-3 ± 1 
 
181 ± 8 
 
-15 ± 3 
mean CBF
LCX  
     (mL·min
-1
) 
30 ± 1 1 ± 1  
30 ± 2  
2 ± 1  
32 ± 2  
-3 ± 2 
 
Data are means ±SEM calculated from n = 11–16 experiments. Data, presented as changes, were determined 5 min after starting the infusion of the 
solvent, simvastatin and L-NAME.*P < 0.05 compared to baseline value. SABP, systolic arterial blood pressure; DABP, diastolic arterial blood 
pressure; MABP, mean arterial blood pressure; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; HR, heart rate; 
CBF, coronary blood flow. 
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Table 2. Haemodynamic changes during a 25 min occlusion of the LAD 
  Solvent   Simvastatin   L-NAME   L-NAME+Simvastatin 
  
Baseline   Max.change   Baseline   Max. 
change 
  Baseline   Max.change   Baseline   Max.change 
SABP (mmHg) 143 ± 10  -11 ± 2*  145 ± 6  -10 ± 2*  166 ± 5  -8 ± 2*  163 ± 8  -10 ± 3* 
DABP (mmHg) 104 ± 6  -11 ± 3*  99 ± 3  -7 ± 2*  133 ± 4  -8 ± 3*  129 ± 7  -11 ± 3* 
MABP (mmHg) 117 ± 6  -12 ± 3*  114 ± 4  -7 ± 2*  144 ± 5  -8 ± 3*  142 ± 8  -11 ± 2* 
LVSP (mmHg) 144 ± 11  -10 ± 3*  145 ± 7  -9 ± 2*  177 ± 5  -9 ± 2*  180 ± 11  -14 ± 5* 
LVEDP (mmHg) 4.7 ± 0.7  9.2 ± 1.5*  5.5 ± 0.3  8.5 ± 1.0*  5.5 ± 0.7  10.0 ± 2.1*  5.0 ± 0.5  9.0 ± 1.0* 
 +dP/dt (mmHg·s
-1
) 2236 ± 212  -568 ± 99*  2670 ± 164  -499 ± 137*  2252 ± 174  -553 ± 165*  2526 ± 317  -566 ± 109* 
 -dP/dt (mmHg·s
-1
) 2183 ± 253  -338 ± 161*  2349 ± 145  -378 ± 68*  2197 ± 174  -491 ± 125*  2317 ± 205  -350 ± 76* 
 HR (beats·min
-1
) 171 ± 9  5 ± 5  170 ± 4  5 ± 3  166 ± 9  3 ± 4  174 ± 11  7 ± 2 
mean CBF
LCX  
    (mL·min
-1
) 
31 ± 2 
 
9 ± 2 
 
30 ± 2 
 
10 ± 2 
 
29 ± 1 
 
9 ± 1 
 
30 ± 2 
 
8 ± 2 
 
Data are means ±SEM calculated from n = 11–16 experiments. *P < 0.05 compared to baseline value. SABP, systolic arterial blood pressure; DABP, diastolic 
arterial blood pressure; MABP, mean arterial blood pressure; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; HR, heart 
rate; CBF, coronary blood flow. 
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4.1.2. The severity of ventricular arrhythmias during a 25 min occlusion of the LAD 
This is shown in Figure 4. In control dogs, occlusion of the LAD resulted in a high 
number of VPBs (289 ± 34) and episodes of VT (5.6 ± 1.3) that occurred in 88% of these 
dogs. Furthermore, 56% of the dogs fibrillated during occlusion and no control dog survived 
reperfusion. Local administration of simvastatin, just prior to the occlusion, significantly 
reduced these arrhythmias (VPBs: 94 ± 25, episodes of VT: 0.3 ± 0.2, incidence of VT: 20%, 
VF: 0%; P < 0.05 compared with controls) during occlusion, and increased survival from 0% 
to 33% compared to the controls. Inhibition of the L-arginine-NO pathway with L-NAME did 
not substantially modify arrhythmia severity during occlusion and reperfusion, but it 
significantly attenuated the antiarrhythmic effect of simvastatin. Thus in the presence of L-
NAME the number of VPBs (438 ± 49), the incidence (100%) and number of episodes of VT 
(6.8 ± 2.9) were again increased in the simvastatin treated dogs, and as in the control group, no 
dog survived the combined ischaemia and reperfusion insult. Interestingly, L-NAME, 
however, did not affect the protective effect of simvastatin against the occlusion-induced 
ventricular fibrillation; i.e. as with simvastatin alone, no dog fibrillated during occlusion in the 
L-NAME+simvastatin group. 
 
Figure 4. The severity of ventricular arrhythmias during a 25 min occlusion and reperfusion 
of the LAD in control (C) and simvastatin (S) treated dogs, and in dogs given L-NAME alone 
or together with simvastatin (L-NAME+S). Values are means ± S.E.M. *P < 0.05 compared to 
the controls.  
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4.1.3. Changes in the severity of myocardial ischaemia during coronary artery occlusion 
This was assessed by two parameters: i.e. changes in the degree of inhomogeneity of 
electrical activation and in epicardial ST-segment In control dogs, occlusion of the LAD 
resulted in immediate and significant increases both in the epicardial ST-segment (Figure 5A) 
and the degree of inhomogeneity of electrical activation (Figure 5B). These changes were 
significantly less pronounced following simvastatin administration. Although L-NAME itself 
did not modify these indices of ischaemia severity, it abolished the anti-ischaemic effects of 
simvastatin. 
 
Figure 5. Changes in the epicardial ST-segment (A) and in the degree of inhomogeneity of 
electrical activation (B) during a 25 min occlusion of the LAD. Values are means ± S.E.M. *P 
< 0.05 compared to the controls. 
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4.1.4. Changes in NOx levels during coronary artery occlusion and reperfusion 
These are shown in Figure 6. A single bolus injection of simvastatin alone or together 
with L-NAME, as well as the solvent of simvastatin, did not affect the plasma NOx levels 
prior to the occlusion. In contrast, L-NAME itself slightly decreased NOx, which was further 
declined during the occlusion. When the LAD was occluded in control animals, a transient 
elevation occurred in the plasma NOx levels (around 7 min of the ischaemia), after which 
NOx started to decrease and became significantly lower than the initial baseline values. In 
contrast, the administration of simvastatin elevated NOx levels almost over the entire 
occlusion period. This effect was completely abolished by the prior administration of L-
NAME. Reperfusion of the ischaemic myocardium evoked similar increases in NOx levels in 
all groups. 
 
Figure 6. Changes in plasma nitrite/nitrate (NOx) levels in the blood of the coronary sinus. 
Values are means ± S.E.M. *P < 0.05 compared to the initial baseline values, and #P < 0.05 
compared to the control group.
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4.1.5. Determination of eNOS activity 
The activity of eNOS was assessed by measuring eNOS phosphorylation with Western 
blot (Figure 7A), whereas the functional activity of the enzyme was determined using radio 
immunoassay (Figure 7B). Compared to the sham-operated controls (n = 5), occlusion of the 
LAD significantly reduced the activity of eNOS by the end of the occlusion period. In 
contrast, simvastatin preserved or even increased both the phosphorylation and the functional 
activity of the enzyme. Although L-NAME alone did not modify the ischaemia-induced 
reduction in eNOS activity, it abolished the simvastatin-induced activation, but not the 
phosphorylation (Figure 7B) of the enzyme. After reperfusion, the function of eNOS was 
rapidly regained in the control dogs, maintained in the simvastatin treated dogs, and remained 
inhibited in dogs given L-NAME. 
 
Figure 7. Changes in NOS phosphorylation (A), and functional activity of eNOS (B) in control 
(C) and simvastatin (S) treated dogs, and in dogs given L-NAME alone or together with 
simvastatin (L-NAME+S). Values are means ± S.E.M. *P < 0.05 cp. SO group, #P < 0.05 
cp..control group, and †P < 0.05 cp. simvastatin group. 
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4.1.6. Changes in myocardial superoxide production following reperfusion 
These are shown in Figure. 8. Compared with the sham controls, in dogs subjected to 
ischaemia and reperfusion a marked increase in superoxide production occurred soon after the 
reopening of the coronary artery. This ischaemia and reperfusion-induced generation of 
superoxide was significantly suppressed by the administration of simvastatin; an effect which 
was reversed by L-NAME.  
 
4.1.7. Changes in QTc interval following coronary artery occlusion  
This was measured in order to assess the potential direct electrophysiological effects of 
simvastatin. The results are illustrated in Figure 9. In control dogs a marked increase 
developed in QTc interval within 5 min of the occlusion and this was maintained during the 
whole ischaemic period. Such a prolongation of the QTc interval was abrogated with 
simvastatin no matter whether L-NAME was present or not.  
Figure 8. Tissue superoxide 
production following a 25 min 
occlusion and reperfusion of the 
LAD in sham-operated (SO), in 
ischaemic control (C) and in 
simvastatin (S) treated dogs, as well 
as in dogs given L-NAME alone or 
together with simvastatin (L-
NAME+S). Values are means ± 
S.E.M. *P < 0.05 compared to the 
SO group and #P < 0.05 compared 
to the control (C) group. 
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Figure 9. Changes in the QTc interval determined prior to and during a 25 min occlusion of 
the LAD. Values are means ± S.E.M. *P < 0.05 compared to the initial baseline values, and #P 
< 0.05 compared to the control group. 
4.1.8. Area at risk  
There were no significant differences in the area at risk among the groups. Thus the 
risk area was 38 ± 2% in the controls, 40 ± 3 % in the simvastatin, 37 ± 3 % in the L-NAME, 
and 39 ± 2% in the L-NAME+simvastatin groups. 
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4.2. Examination of the role of the IP3-kinase pathway in the simvastatin-induced rapid 
activation of eNOS  
This was examined by the use of the specific IP3-kinase inhibitor wortmannin. 
4.2.1. Haemodynamic changes following the administration of solvent, simvastatin, 
wortmannin and DMSO, as well as after coronary artery occlusion  
These data are summarised in Tables 3 and 4. There were no considerable changes in 
the haemodynamic parameters following the local intracoronary injection of simvastatin and 
wortmannin, as well as of the vehicle of these drugs (Table 1). Although occlusion of the LAD 
resulted in signiﬁcant reductions in arterial blood pressure, LVSP, positive and negative 
dP/dtmax, and an increase in LVEDP in all groups, these changes were not substantially 
different among the groups. The compensatory blood ﬂow changes, occurring during the 
occlusion of the LAD on the LCX coronary artery, were not significantly modified by any 
drug treatment. Furthermore, in anaesthetised dogs HR was unchanged during coronary artery 
occlusion in all groups (Table 4). 
4.2.2. The severity of ventricular arrhythmias during a 25 min occlusion of the LAD 
This is illustrated in Figure 10. In control dogs occlusion of the LAD resulted in high 
number of VPBs (310 ± 45) and episodes of VT (7.1 ± 1.4) that occurred in 93%of the dogs. 
Furthermore, 50% of these control dogs exhibited VF during the occlusion and all the 
remaining dogs died on reperfusion, thus there were no survivors in this group from the 
combined ischaemia and reperfusion insult. In contrast, the single dose of simvastatin 
markedly reduced the number of ectopic beats (62 ± 14) and episodes of VT (0.3 ± 0.2), the 
incidences of VT (17%) and VF (0%) during occlusion, and 67% of the animals survived 
reperfusion. The administration of wortmannin in the simvastatin treated dogs significantly 
reduced this antiarrhythmic protection. 
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Table 3. Haemodynamic changes following solvent, wortmannin, DMSO and simvastatin administration. 
  Solvent   Wortmannin   DMSO   Simvastatin 
  Baseline   Change   Baseline   Change   Baseline   Change   Baseline   Change 
SABP (mmHg) 143 ± 7  3 ± 2  131 ± 4  0 ± 2  135 ± 6  2 ± 2  151 ± 7  -4 ± 2 
DABP (mmHg) 105 ± 5  0 ± 4  96 ± 3  0 ± 2  93 ± 5  0 ± 1  103 ± 4  -2 ± 2 
MABP (mmHg) 118 ± 5  1 ± 3  109 ± 3  0 ± 2  108 ± 5  0 ± 1  119 ± 5  -4 ± 1 
LVSP (mmHg) 154 ± 7  2 ± 2  139 ± 4  1 ± 2  146 ± 5  0 ± 2  163 ± 7  -1 ± 2 
LVEDP (mmHg) 4.3 ± 0.6  0.5 ± 0.3  4.0 ± 0.5  0.5 ± 0.5  3.3 ± 0.4  0.1 ± 0.2  5.3 ± 0.4  0 ± 0.2 
 +dP/dt (mmHg/s) 2351 ± 184  90 ± 50  2186 ± 160  -75 ± 43  2398 ± 116  61 ± 55  2787 ± 180  -79 ± 98 
 -dP/dt (mmHg/s) 2266 ± 213  40 ± 81  2443 ± 159  -5 ± 112  2676 ± 181  65 ± 71  2506 ± 216  -28 ± 50 
 HR ( beats/min) 163 ± 7  4 ± 2  156 ± 5  -3 ± 1  156 ± 4  1 ± 1  169 ± 5  -3 ± 1 
mean CBFLCX 
(ml/min) 
42 ± 5  -1 ± 2  25 ± 3  3 ± 2  28 ± 4  -1 ± 1  32 ± 8  1 ± 2 
                                
Data are means ± S.E.M. calculated from n = 11–14 experiments. Data, presented as changes, were determined 5 min after starting the infusion of the solvent, wortmannin, 
DMSO and simvastatin. SABP, systolic arterial blood pressure; DABP, diastolic arterial blood pressure; MABP, mean arterial blood pressure; LVSP, left ventricular 
systolic pressure; LVEDP, left ventricular end-diastolic pressure; HR, heart rate; CBF, coronary blood flow. 
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Table 4. Haemodynamic changes during a 25 min occlusion of the LAD. 
  Control Wortmannin DMSO Simvastatin Wortmannin+Simvastatin 
  Baseline Max.change Baseline Max.change Baseline Max.change Baseline Max. change Baseline Max.change 
SABP (mmHg) 146 ± 7 -10 ± 2* 135 ± 5 -11 ± 2* 137 ± 7 -11 ± 2* 148 ± 5 -11 ± 2* 155 ± 8 -10 ± 2* 
DABP (mmHg) 105 ± 5 -10 ± 3* 99 ± 4 -8 ± 1* 93 ± 6 -9 ± 2* 101 ± 3 -7 ± 2* 116 ± 7 -7 ± 2* 
MABP (mmHg) 119 ± 5 -10 ± 3* 111 ± 4 -9 ± 2* 108 ± 6 -10 ± 2* 117 ± 4 -8 ± 2* 129 ± 7 -8 ± 2* 
LVSP (mmHg) 146 ± 9 -10 ± 2* 148 ± 6 -10 ± 2* 150 ± 7 -15 ± 2* 152 ± 7 -11 ± 2* 164 ± 8 -11 ± 2* 
LVEDP (mmHg) 4.5 ± 0.6 9.3 ± 1.3* 4.4 ± 0.6 9.6 ± 1.0* 3.4 ± 0.5 13.2 ± 1.0* 5.2 ± 0.3 9.0 ± 0.9* 4.5 ± 0.6 9.6 ± 1.1* 
 +dP/dt (mmHg/s) 2310 ± 157 -495 ± 81* 2143 ± 161 -346 ± 66* 2586 ± 155 -534 ± 109* 2673 ± 135 -495 ± 114* 2411 ± 181 -358 ± 93* 
 -dP/dt (mmHg/s) 2316 ± 200 -425 ± 139* 2446 ± 215 -540 ± 82* 2656 ± 210 -624 ± 111* 2563 ± 183 -504 ± 91* 2518 ± 159 -426 ± 113* 
HR ( beats/min) 166 ± 7 4 ± 4 154 ± 7 1 ± 2 162 ± 5 3 ± 2 167 ± 4 4 ± 2 162 ± 5 4 ± 2 
mean CBFLCX 
(ml/min) 41 ± 5 13 ± 2 26 ± 3 13 ± 4 30 ± 3 11 ± 2 32 ± 2 10 ± 1 39 ± 6 12 ± 2 
                                                              
Data are means ±S.E.M. calculated from n = 11–14 experiments. aP< 0.05 compared to baseline value. SABP, systolic arterial blood pressure; DABP, diastolic arterial 
blood pressure; MABP, mean arterial blood pressure; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; HR, heart rate; CBF, 
coronary blood flow. 
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Thus in the presence of wortmannin the number of VPBs (30 ± 759), the incidence (73%) and 
number of episodes of VT (4.3 ± 1.3) were again increased, and as with the controls (C and 
DMSO groups), no dog in the W+S group survived reperfusion. However, wortmannin, like L-
NAME before (see 4.1.2) did not modify the effect of simvastatin on the ischaemia-induced 
VF; i.e. as with simvastatin alone, no dog in the W+S group died in VF during the occlusion 
period. Compared to the controls (C), neither wortmannin, nor DMSO, the vehicle of 
wortmannin, affected the severity of arrhythmias resulted from a 25 min LAD occlusion and 
reperfusion. Thus in these groups the number of VPBs was 202 ± 64 and 246 ± 36, further 
67% and 69% of these dogs exhibited 3.8 ± 1.7 and 3.8 ± 1.6 episodes of VT, and 25% and 
23% of the animals showed VF during the occlusion. In these groups none of the dogs 
survived reperfusion.  
 
Figure 10. The severity of ventricular arrhythmias during a 25 min occlusion and reperfusion 
of the LAD in control (C) and in simvastatin (S) treated dogs, as well as in dogs in which 
DMSO and wortmannin (W) was given alone or together with simvastatin (W+S). Values are 
means ± S.E.M. *P < 0.05 compared to the controls. 
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4.2.3. Changes in ischaemia severity during a 25 min occlusion of the LAD 
This was assessed by changes in the epicardial ST-segment (Figure 11A) and in the 
degree of inhomogeneity of electrical activation (Figure 11B). In the control groups (C and 
DMSO) there were marked increases in both parameters over the entire occlusion period. 
Simvastatin markedly suppressed these indices of ischaemia severity, which effect was 
completely abolished in the presence of wortmannin. Inhibition of the PI 3-kinase by 
wortmannin had no significant effect on these ischaemia-induced inhomogeneity and ST-
segment changes. 
 
Figure 11. Changes in epicardial ST-segment (A) and in the degree of inhomogeneity of 
electrical activation (B) during a 25 min occlusion of the LAD. Values are means ± S.E.M. *P 
< 0.05 compared to the controls. 
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4.2.4. Determination of eNOS activity  
Compared to the sham controls (instrumented but not subjected to ischaemia; SC), in 
dogs, infused either with the solvent of simvastatin (C) or DMSO and subjected to occlusion, 
there was a signiﬁcant decrease in eNOS phosphorylation (Figure 12A). The administration of 
simvastatin preserved, or even slightly increased the activity of eNOS during the occlusion. 
This effect was abolished in the presence of wortmannin (W+S group), although wortmannin 
(W group) alone did not affect the ischaemia-induced changes in NOS phosphorylation. When 
the coronary artery was re-opened, it can be seen that NOS regained very rapidly (these data 
were collected at different times of the reperfusion according to the occurrence of VF within 
the 5 min observation period; Figure 12B). Thus following reperfusion the phosphorylation of 
eNOS was increased in almost all groups, except those that had been received wortmannin (W 
and W+S groups) prior to the 25 min occlusion and reperfusion of the LAD. 
 
Figure 12. Changes in the phosphorylated eNOS content, determined by Western blot at the 
end of the coronary artery occlusion, and 5 min after reperfusion. Values are means ± S.E.M. 
*P < 0.05 compared to the SC group, #P < 0.05 compared to the ischaemic control (C) group, 
and †P < 0.05 compared to the simvastatin group. 
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4.2.5. Changes in NOx levels during coronary artery occlusion and reperfusion  
These are illustrated in Figure 13. In control dogs occlusion of the LAD resulted in a 
transient, but signiﬁcant increase in NOx (peaked around 7 min of the occlusion), followed by 
a continuous decrease up to the end of the 25 min occlusion period. This ischaemia-induced 
reduction in NOx was prevented by the application of a single dose of simvastatin. The 
administration of wortmannin in control dogs abolished the early increase of NO metabolites, 
and it completely abrogated the NO preserving effect of simvastatin over the entire occlusion 
period. DMSO had no effect on NO bioavailability during occlusion and reperfusion.  
 
Figure 13. Changes in plasma nitrite/nitrate (NOx) levels in the blood of the coronary sinus. 
Values are means ± S.E.M. *P < 0.05 compared to the initial baseline values, and #P < 0.05 
compared to the control group. 
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4.2.6. Changes in myocardial superoxide production following reperfusion  
In dogs that had been subjected to reperfusion following a 25 min period of ischaemia, 
myocardial superoxide production was determined within 5 min of the reperfusion, 
irrespective whether these dogs died or survived. The results are illustrated in Figure 14. 
Compared to the sham controls, in dogs subjected to occlusion and reperfusion, there was a 
marked increase in superoxide production, which was significantly reduced by simvastatin. 
The administration of DMSO, as well as of wortmannin itself, did not affect the 
ischaemia/reperfusion-induced generation of superoxide, but wortmannin reversed the effect 
of simvastatin on superoxide production.  
Figure 14. Tissue superoxide production following a 25 min occlusion and reperfusion of the 
LAD. Values are means ± S.E.M. *P < 0.05 compared to the SC group and #P < 0.05 
compared to the control (C) group. 
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4.2.7. Changes in QTc interval following coronary artery occlusion 
As we have previously described, simvastatin prevents the ischaemia-induced 
prolongation of the QTc interval, indicating a possible direct electrophysiological effect of the 
drug (see 4.1.7.). We have now shown that similar to L-NAME, in the presence of wortmannin 
the effect of simvastatin on the QTc interval was still maintained (Figure 15). 
Figure 15. Changes in the QTc interval determined prior to and during a 25 min occlusion of 
the LAD. Values are means ± S.E.M. *P < 0.05 compared to the initial baseline values, and #P 
< 0.05 compared to the control group. 
4.2.8. Area at risk 
There were no signiﬁcant differences in the area at risk among the groups. Thus the 
risk area was 37 ± 3% in the controls, 38 ± 2% in the simvastatin, 39 ± 2% in the wortmannin, 
37 ± 2% in the wortmannin+simvastatin and 39 ± 3% in the DMSO groups. 
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5. DISCUSSION 
5.1. New findings 
1. We have provided evidence that a single dose of simvastatin, applying just prior to a 25 min 
period of coronary artery occlusion in anaesthetized dogs, results in profound protection 
against those severe ventricular arrhythmias that are, in most instances, responsible for sudden 
cardiac death. We have also pointed out that this antiarrhythmic effect of simvastatin, at least 
in part, is due to an increased nitric oxide production, resulting from the rapid activation of the 
endothelial nitric oxide synthase (eNOS) by simvastatin, since the protective effect of 
simvastatin was almost completely abolished in the presence of the NOS enzyme inhibitor L-
NAME. 
2. We have also shown that the simvastatin-induced rapid eNOS activation results from the 
stimulation of the IP3/Akt pathway, since the inhibition of the IP3-kinase with wortmannin, 
attenuates eNOS activation and, consequently, abolishes the antiarrhythmic protection. 
5.2. The effect of acute simvastatin administration on ischaemia and reperfusion 
ventricular arrhythmias. The role of nitric oxide. 
The evidence that statins may reduce the incidence of life-threatening ventricular 
arrhythmias and prevent sudden cardiac death, comes mainly from large clinical studies with 
chronic statin treatment [51, 52 66, 101]. There has been much less information, apart from a 
few clinical investigations [102, 103], whether these drugs, following acute administration, 
would influence the consequences of ischaemia and reperfusion, including the life threatening 
ventricular arrhythmias [77, 96]. Furthermore, since many of the beneficial effects of statins 
have been shown to involve increased synthesis of nitric oxide [81, 93], and since we have a 
number of previous evidence that NO plays an essential role in the protection against the 
ischaemia-induced early arrhythmias [29, 30], we have now examined whether the effect of 
simvastatin on arrhythmias is also due to the activation of eNOS and the subsequent increase 
in NO formation. 
The results show that in anaesthetized dogs the administration of a single dose of 
simvastatin markedly reduced the number of VPBs and episodes of VT, the incidence of VT 
and VF that resulted from a 25 min occlusion of the LAD and increased survival from the 
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combined ischaemia and reperfusion insult, compared with the untreated controls. This 
protection against arrhythmias was similar to that we have obtained previously, in the same 
model, with ischaemic preconditioning [7], and with the administration of NO donors [48, 
100, 104]. Furthermore, simvastatin significantly reduced the severity of ischaemic changes 
during coronary artery occlusion. These salutary effects of simvastatin administration were 
associated with increased eNOS activity since the phosphorylation of eNOS (determined by 
Western blot) and the functional activity of this enzyme (determined by RIA) were 
significantly higher during ischaemia and reperfusion in the simvastatin treated dogs than in 
the solvent treated controls (Figure 7). This activation of eNOS by simvastatin resulted in an 
increased generation of NO during occlusion (Figure 6) and also a decrease in superoxide 
production following reperfusion (Figure 8). As we have shown previously, the preservation of 
NO bioavailability during coronary artery occlusion by preconditioning or by donating NO, 
attenuates the reperfusion-induced marked increases of superoxide production [100], since NO 
may regulate the generation of superoxide during reperfusion [43]. These effects are certainly 
can be associated with the antiarrhythmic effect of simvastatin. Furthermore, the fact that L-
NAME prevented the simvastatin activated enzyme to form NO (inhibits the L-arginine-NO 
pathway without affecting enzyme phosphorylation) and attenuated or even abolished most of 
the salutary effects of simvastatin, supports the hypothesis that the eNOS activated NO 
formation plays a crucial role in the protective effect of simvastatin against arrhythmias.  
We have raised the question, how the activation of eNOS takes place following a single 
dose of simvastatin. There are a few studies in the literature, which show that statins can 
rapidly activate eNOS by stimulating the phoshatidylinositide 3-kinase/Akt (PI 3-kinase/Akt) 
pathway [93, 95, 119]. For example, in the study of Wolfrum and colleagues [95], simvastatin 
given in anaesthetised rats 3 min prior to reperfusion markedly reduced infarct size that 
resulted from a 30 min coronary artery occlusion and a subsequent 180 min period of 
reperfusion. They also showed that simvastatin increased myocardial PI 3-kinase activity, and 
enhanced AktSer473 and eNOSSer1177 phosphorylation. Since the infarct size reducing effect of 
simvastatin was abolished by the administration of the PI 3-kinase inhibitor wortmannin and 
of the NOS inhibitor L-NAME, they concluded that the activation of PI 3-kinase/Akt/eNOS 
cascade plays an important role in the acute cardioprotective effects of simvastatin [95]. 
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On the basis of the abovementioned study, in the second part of the experiments we 
examined, whether the antiarrhythmic effect of acute simvastatin administration involves the 
rapid activation of the PI 3-kinase/Akt/eNOS signalling pathway. For this purpose we have 
also used wortmannin, a potent and specific inhibitor of PI 3-kinase, and administered in dogs 
prior to the bolus injection of simvastatin. We have found that in the presence of wortmannin 
most of the salutary effects of simvastatin were attenuated, or even abolished. Thus the 
number of VPBs, the number of episodes of VT and the incidence of VT during occlusion 
were again increased, and compared with the simvastatin treated group, in which 40 % of the 
dogs survived reperfusion, in the wortmannin + simvastatin group (W + S) no animal survived 
the combined ischaemia and reperfusion insult. The pre-treatment with wortmannin 
significantly attenuated the simvastatin induced activation of eNOS and the subsequent NO 
production, as well as the decreases in superoxide generation. The marked anti-ischaemic 
effect of simvastatin was also abolished by the administration of wortmannin.  
There is still ongoing debate as to whether the reduction in tachyarrhythmias (VT and 
VF) that are responsible in most instances for sudden cardiac death, is due to the anti-
ischaemic effect of statins, or there might be a more direct electrophysiological action of these 
drugs, which would explain their marked antiarrhythmic effect. A recent review from Beri et 
al. [105] has addressed this question by collecting and systematically evaluating data 
published over a 13-year period on the reduction of VT and VF events, as well as sudden 
cardiac death in patients suffering from various cardiovascular diseases and treated with 
statins. They concluded that the anti-arrhythmic/anti-fibrillatory effects of statins most 
probably result from an anti-ischaemic rather than a direct anti-arrhythmic effect, since a 
definitive reduction in sudden cardiac death occurred only in patients with ischaemic-type 
cardiovascular diseases, such as coronary artery disease or ischaemic cardiomyopathy [105]. 
These anti-ischaemic effects of statins are supposed to mediate through nitric oxide and can 
indirectly influence the generation of arrhythmias [105]. 
Although we have found that simvastatin results in pronounced anti-ischaemic effect, 
since the increases in the epicardial ST-segment and in the degree of inhomogeneity during 
occlusion were significantly less marked in the simvastatin treated dogs than in the controls, 
we suppose that simvastatin might possesses a direct anti-arrhythmic effect as well. The 
evidence for this assumption may come from two observations; i.e. (i) despite the abolition of 
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the anti-ischaemic effect of simvastatin by L-NAME (Figure 5) and wortmannin (Figure 11), 
the protective effect of simvastatin against the ischaemia-induced ventricular fibrillation was 
still present, and (ii) neither L-NAME nor wortmannin did not influence the reduction in QTc 
interval, resulted from simvastatin administration (Figure 15). However, interestingly, both 
inhibitors abolished the protective effect of simvastatin against the reperfusion-induced VF. 
The explanations for this dichotomy could be many and varied, including differences in the 
underlying mechanisms of the various arrhythmia types induced by the acute ischaemia [106, 
107], as well as differences in the local and systemic regulatory influences of NO on 
arrhythmia mechanisms. These latter may involve, for example, the modulation of the effect of 
autonomic tone on the myocardium [41] and of gap junction function [48], as well as the 
regulation of free radical formation by NO [43, 100].  
Nevertheless, the fact that L-NAME and wortmannin did not influence the protective 
effect of simvastatin against the occlusion-induced ventricular fibrillation suggests that in the 
anti-fibrillatory effect of simvastatin, there might be an NO-independent and, perhaps, a more 
direct electrophysiological mechanism. This assumption is supported by the results of the QTc 
interval measurements. These show that simvastatin almost completely inhibited the 
ischaemia-induced prolongation of the QTc interval, and this effect was not modified by the 
administration of L-NAME or wortmannin. Although we cannot ascertain the precise 
mechanism of this phenomenon only from the measurement of QTc intervals, recent 
electrophysiological studies suggest that statins influence impulse conduction, improve cardiac 
repolarization [108, 109] and suppress cardiac excitability [110] perhaps by directly and 
selectively affecting ion channels in cardiomyocytes (e.g. Kv4.3; [111]). Certainly, long-term 
statin treatment by modulating the lipid portions of the sarcolemma, which contain the ion 
channel regulatory proteins and signalling molecules (lipid rafts), influence the ion channel 
conduction and ion transport [112, 113], but it is not known whether such a mechanism would 
also account for the acute administration of statins. Nevertheless, considering that 
polyunsaturated fatty acids, which alter the structure of the sarcolemmal phospholipids, were 
able to evoke immediate antiarrhythmic effect [114-116], we may speculate that statins 
perhaps also possess such acute modulator properties on the lipid portions of the membrane. 
This, by causing favourable changes in ion transport or by stabilizing the membrane, would 
lead to arrhythmia suppression during ischaemia. 
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In contrast, the fact that L-NAME and wortmannin abrogated the protective effect of 
simvastatin against the reperfusion-induced VF suggests that this action depends more on NO 
bioavailability than the ischaemia-induced VF [48]. Considering the electrophysiological 
differences between the ischaemia-induced and the reperfusion-induced arrhythmias [106], 
and that, in this latter, the products of the oxidative stress and the calcium overload [117] play 
a mandatory role, it seems more than likely that simvastatin through an NO-dependent way 
[118] reduces superoxide production and hence the occurrence of VF during reperfusion. 
Consequently, this protection disappears by inhibiting the formation of NO. 
Summarizing our results, we have shown that a single bolus injection of simvastatin 
markedly reduces the ischaemic changes and the incidence and severity of ventricular 
arrhythmias that results from a 25 min occlusion and reperfusion in anaesthetized dogs. 
Furthermore, we have demonstrated that the simvastatin-induced marked antiarrhythmic effect 
largely depends on the generation of NO that results from the rapid activation of eNOS via the 
stimulation of the PI 3-kinase/Akt pathway. The evidence for this is that most of the salutary 
effects of simvastatin (except the protection against the occlusion-induced VF) are attenuated 
or even abolished, if PI 3-kinase, one of the upstream components of NOS activation is 
inhibited with wortmannin. Thus we think that the activation of PI 3-kinase/Akt/eNOS cascade 
and the subsequent increased formation of NO play a crucial role in the antiarrhythmic effect 
of acute simvastatin administration, but a direct and presumably NO-independent mechanism 
cannot be ruled out. 
Considering these findings our hypothesis is that simvastatin, like a short (5 min) 
period of ischaemia rapidly activates NOS and results in enhanced NO formation. However, 
the ischaemia-induced elevation in NO formation is transient, if the ischaemia is not 
reperfused, but it is maintained over a longer period (e.g. 25 min), then the activity of NOS, 
and consequently, the NO production, are markedly reduced [120]. Furthermore, we suppose 
that both simvastatin and a short period of ischaemia/reperfusion insult (i.e. preconditioning, 
[120]), is able to rapidly activate NOS, and in this case the enzyme remains to be activated and 
provides increased NO bioavailability over the entire prolonged period of the ischaemia [120]. 
The fact that in both cases the NOS activation can be blocked by L-NAME [29, 95], and also 
by wortmannin [95, 121], suggests that there might be a common pathway in NOS activation 
both by simvastatin and preconditioning. Indeed, there is evidence coming mainly from in 
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vitro experiments that phosphorylation of NOS rapidly modifies NOS activity [122]. For 
example, it has been recently reported that in the rat isolated hearts, preconditioning, by 
stimulating the Akt/protein kinase A (PKA) pathway, activates eNOS via serine 1176 
phosphorylation [123]. There is also evidence that the PI 3-kinase inhibitor wortmannin 
abolished the preconditioning-induced phosphorylation of protein kinase B (Akt) and the 
increase in NO production in Langendorff-perfused rat hearts [121]. 
We are convinced that NO bioavailability during occlusion plays an essential role in 
arrhythmia generation both during occlusion and reperfusion [29, 48, 100, 120]. Thus any 
manoeuvre, which increases or, at least, maintains NO formation during occlusion may protect 
the myocardium against arrhythmias, most probably through the regulation of those local and 
systemic mechanisms by NO that are implicated in arrhythmia generation, such as the 
autonomic tone [41], gap junctional function [48, 124], or the formation of free radicals [43, 
100], etc. The latter is particularly important in the generation of the reperfusion-induced 
severe ventricular arrhythmias, and NO by reducing free radical formation (most likely 
superoxide) may suppress the occurrence of arrhythmias during reperfusion [100]. Since both 
L-NAME and wortmannin abolished the suppressing effect of simvastatin on the reperfusion-
induced superoxide production and subsequently increased the incidence of VF during 
reperfusion, it seems more than likely that this effect of simvastatin is NO-dependent and it 
attains via the activation of the PI 3-kinase/Akt/eNOS pathway. On the other hand, those of 
our findings which show that the inhibition of NO formation does not influence the protective 
effect of simvastatin against the occlusion-induced VF indicates an NO-independent, direct 
electrophysiological mechanism in the anti-fibrillatory effect of simvastatin. 
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